Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency - PubMed (original) (raw)
Case Reports
. 2002 Oct;110(8):1093-103.
doi: 10.1172/JCI15693.
Giuseppe Matarese, Graham M Lord, Julia M Keogh, Elizabeth Lawrence, Chizo Agwu, Veronica Sanna, Susan A Jebb, Francesco Perna, Silvia Fontana, Robert I Lechler, Alex M DePaoli, Stephen O'Rahilly
Affiliations
- PMID: 12393845
- PMCID: PMC150795
- DOI: 10.1172/JCI15693
Case Reports
Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency
I Sadaf Farooqi et al. J Clin Invest. 2002 Oct.
Abstract
The wide range of phenotypic abnormalities seen in the leptin-deficient ob/ob mouse and their reversibility by leptin administration provide compelling evidence for the existence of multiple physiological functions of this hormone in rodents. In contrast, information regarding the roles of this hormone in humans is limited. Three morbidly obese children, who were congenitally deficient in leptin, were treated with daily subcutaneous injections of recombinant human leptin for up to 4 years with sustained, beneficial effects on appetite, fat mass, hyperinsulinemia, and hyperlipidemia. Leptin therapy resulted in a rapid and sustained increase in plasma thyroid hormone levels and, through its age-dependent effects on gonadotropin secretion, facilitated appropriately timed pubertal development. Leptin deficiency was associated with reduced numbers of circulating CD4(+) T cells and impaired T cell proliferation and cytokine release, all of which were reversed by recombinant human leptin administration. The subcutaneous administration of recombinant human leptin has major and sustained beneficial effects on the multiple phenotypic abnormalities associated with congenital human leptin deficiency.
Figures
Figure 1
Effects of r-metHuLeptin on weight in three children with congenital leptin deficiency. (a) Weights of child A compared with normal centiles for girls and of child B and child C compared with normal centiles for boys. Arrows indicate the start of r-metHuLeptin therapy. (b) Clinical photographs of child B before (height = 107 cm) and 24 months after r-metHuLeptin therapy (height = 124 cm) (reproduced with the permission of the child’s parents).
Figure 2
Effects of r-metHuLeptin therapy on energy intake. (a) Energy intake at an ad libitum test meal before (black bars) and 2 months after (white bars) r-metHuLeptin therapy in child A, B, and C. Energy intake (KJ) expressed per kilogram lean body mass to compare intake of subjects of different age and body size. (b) Changes in body mass index SDS (BMI SDS) (filled symbols) and energy intake at an 18-MJ ad libitum test meal (gray bars) during 36 months of treatment in child B. Panels indicate duration of r-metHuLeptin dose expressed as a percentage of predicted serum leptin concentration based on age, gender, and body composition.
Figure 3
Leptin therapy results in pubertal development at an appropriate developmental age. (a) Pulsatile secretion of LH and FSH in child A after 12 and 24 months of r-metHuLeptin therapy. (b) No pulsatile secretion after 12 months of treatment in child B.
Figure 4
Effect of r-metHuLeptin on T cell proliferation and cytokine production in child C. (a) Proliferative responses of peripheral lymphocytes to T cell–specific stimuli at three different time points before (–) and after (+) recombinant leptin treatment. All data are from triplicate cultures and expressed as mean ± SD. Proliferative responses from normal age-matched controls were measured in parallel experiments (mean shown as single point ± SD). (b) Cytokine profiles in child C at three different time points before (–) and after (+) recombinant leptin treatment. Cytokine measurements from normal age-matched controls were measured in parallel experiments (mean shown as single point ± SEM).
Similar articles
- Congenital leptin deficiency due to homozygosity for the Delta133G mutation: report of another case and evaluation of response to four years of leptin therapy.
Gibson WT, Farooqi IS, Moreau M, DePaoli AM, Lawrence E, O'Rahilly S, Trussell RA. Gibson WT, et al. J Clin Endocrinol Metab. 2004 Oct;89(10):4821-6. doi: 10.1210/jc.2004-0376. J Clin Endocrinol Metab. 2004. PMID: 15472169 - Long-Acting PASylated Leptin Ameliorates Obesity by Promoting Satiety and Preventing Hypometabolism in Leptin-Deficient Lep(ob/ob) Mice.
Bolze F, Morath V, Bast A, Rink N, Schlapschy M, Mocek S, Skerra A, Klingenspor M. Bolze F, et al. Endocrinology. 2016 Jan;157(1):233-44. doi: 10.1210/en.2015-1519. Epub 2015 Oct 22. Endocrinology. 2016. PMID: 26492472 - Narrative review: the role of leptin in human physiology: emerging clinical applications.
Kelesidis T, Kelesidis I, Chou S, Mantzoros CS. Kelesidis T, et al. Ann Intern Med. 2010 Jan 19;152(2):93-100. doi: 10.7326/0003-4819-152-2-201001190-00008. Ann Intern Med. 2010. PMID: 20083828 Free PMC article. Review. - Ten years of leptin replacement therapy.
Paz-Filho G, Wong ML, Licinio J. Paz-Filho G, et al. Obes Rev. 2011 May;12(5):e315-23. doi: 10.1111/j.1467-789X.2010.00840.x. Epub 2011 Mar 17. Obes Rev. 2011. PMID: 21410864 Review. - Leptin in human physiology and therapeutics.
Dardeno TA, Chou SH, Moon HS, Chamberland JP, Fiorenza CG, Mantzoros CS. Dardeno TA, et al. Front Neuroendocrinol. 2010 Jul;31(3):377-93. doi: 10.1016/j.yfrne.2010.06.002. Epub 2010 Jun 17. Front Neuroendocrinol. 2010. PMID: 20600241 Free PMC article. Review.
Cited by
- Association of systemic immune-inflammation index with body mass index, waist circumference and prevalence of obesity in US adults.
Yang S, Zhang S, Deng J, Xie J, Zhang J, Jia E. Yang S, et al. Sci Rep. 2024 Sep 27;14(1):22086. doi: 10.1038/s41598-024-73659-3. Sci Rep. 2024. PMID: 39333666 Free PMC article. - The Role of Adipocytes Recruited as Part of Tumor Microenvironment in Promoting Colorectal Cancer Metastases.
Ma Y, Nenkov M, Chen Y, Gaßler N. Ma Y, et al. Int J Mol Sci. 2024 Jul 30;25(15):8352. doi: 10.3390/ijms25158352. Int J Mol Sci. 2024. PMID: 39125923 Free PMC article. Review. - Novel compound heterozygous mutations in LEP responsible for obesity in a Chinese family.
Li H, Liu G, Lu B, Zhou X. Li H, et al. Mol Genet Metab Rep. 2024 Jun 29;40:101114. doi: 10.1016/j.ymgmr.2024.101114. eCollection 2024 Sep. Mol Genet Metab Rep. 2024. PMID: 39041042 Free PMC article. - Glutamate neurotransmission from leptin receptor cells is required for typical puberty and reproductive function in female mice.
Sáenz de Miera C, Bellefontaine N, Allen SJ, Myers MG, Elias CF. Sáenz de Miera C, et al. Elife. 2024 Jul 15;13:RP93204. doi: 10.7554/eLife.93204. Elife. 2024. PMID: 39007235 Free PMC article. - Updates on Rare Genetic Variants, Genetic Testing, and Gene Therapy in Individuals With Obesity.
Zuccaro MV, LeDuc CA, Thaker VV. Zuccaro MV, et al. Curr Obes Rep. 2024 Sep;13(3):626-641. doi: 10.1007/s13679-024-00567-y. Epub 2024 Jun 1. Curr Obes Rep. 2024. PMID: 38822963 Review.
References
- Zhang Y, et al. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994;372:425–432. - PubMed
- Swerdloff RS, Batt RA, Bray GA. Reproductive hormonal function in the genetically obese (ob/ob) mouse. Endocrinology. 1976;98:1359–1364. - PubMed
- Dubuc PU. Basal corticosterone levels of young ob/obmice. Horm Metab Res. 1977;9:95–97. - PubMed
- Trayhurn P, Thurlby PL, James WPT. Thermogenic defect in pre-obese ob/obmice. Nature. 1977;266:60–62. - PubMed
- Ohtake M, Bray GA, Azukizawa M. Studies on hypothermia and thyroid function in the obese (ob/ob) mouse. Am J Physiol. 1977;233:110–115. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous